{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 73 of 92', 'CR845-CLIN3103', 'with an onset date after the first dose of the double-blind study drug up to the first', 'dose of open-label drug for patient who continue into the Open-label Extension', 'Phase.', 'The number and percentage of patients experiencing TEAEs will be summarized by', 'treatment group and by period. A patient will be counted only once in the incidence', 'count for a MedDRA SOC or Preferred Term, although a patient may have multiple', 'occurrences (start and stop) of an event associated with a specific MedDRA Preferred', 'Term or SOC. The most frequent TEAEs (>5% of patients in any treatment group) will', 'also be tabulated by SOC and Preferred Term.', 'The incidence and percentage of patients experiencing treatment-emergent SAEs and', 'TEAEs leading to study discontinuation will be presented by the appropriate MedDRA', 'SOC and Preferred Term. Adverse events that result in death will also be summarized.', 'Treatment-emergent adverse events will also be summarized by severity for each study', 'period of the Double-blind Phase and by relationship to double-blind study drug for the', 'Double-blind Period. If the severity and/or relationship to the study drug of an adverse', 'event is missing, a worst-case scenario will be assumed (ie, the adverse event will be', 'categorized as \"severe\" and/or \"related\" to the study drug). If a patient reports the same', 'TEAE multiple times the event with the worst severity and the strongest relationship to', 'study drug will be tabulated.', 'For each period of the Double-blind Phase, an overall summary table will be provided,', 'presenting for each treatment group: the number and percentage of patients with an', 'adverse event (both treatment and non-treatment emergent) during that period, a TEAE,', 'serious TEAE, related TEAE, severe TEAE, TEAE leading to dose interruption, and', 'TEAE leading to study drug discontinuation. This table will also include the number of', 'events for each specific Preferred Term.', 'All adverse events will be listed in chronological order, including patient identifier, age,', 'race, gender, a flag indicating whether the event was treatment-emergent and all related', 'event status information (start and stop dates, whether the event was ongoing, study day', 'of onset, severity, seriousness, relationship to study medication, action taken with study', 'treatment, and outcome). Separate listings will be generated for SAEs, deaths, and', 'adverse events leading to study drug discontinuation. Additionally, a coding list of', 'Preferred Terms and the verbatim text associated with them will be produced.', '8.8.3', 'Clinical Laboratory Evaluations', 'Summary statistics for each scheduled time point measured and mean changes from', 'baseline to each time point (when applicable) will be presented for clinical laboratory', 'results.', 'All laboratory evaluation summaries will include the patients in the Double-blind Safety', 'Population who have at least 1 postbaseline time point (for criteria based on postbaseline', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 74 of 92', 'CR845-CLIN3103', 'assessments) and with both a baseline and at least 1 postbaseline time point (for criteria', 'evaluating changes from baseline).', 'Laboratory values will be reported in Syst\u00e8me International units.', 'Laboratory test results will be assigned an L/N/H classification according to whether the', \"value was below (L), within (N), or above (H) the laboratory parameter's reference range.\", 'Comparisons will be based on 3x3 tables (shift tables) that, for a particular laboratory', 'test, compare the baseline L/N/H classification to the highest and/or lowest L/N/H', 'classification during the treatment period. Clinically important laboratory values based', 'on prespecified criteria defined in the SAP will also be summarized.', 'Additionally, alanine aminotransferase, aspartate aminotransferase, bilirubin, and alkaline', 'phosphatase will be presented in a separate listing, with 3x and 5xULN flagged for', 'alanine aminotransferase and aspartate aminotransferase; 2xULN flagged for bilirubin,', 'and 1.5xULN flagged for alkaline phosphatase.', '8.8.4', 'Vital Signs and ECGs', 'Summary tables will include descriptive statistics for baseline and each postbaseline', 'assessment. Descriptive statistics will be calculated on both the actual score and the', 'change from baseline score. Baseline is defined as the last measurement taken on or prior', 'to the first day of dosing. Note that the Day 1 assessment can be included in the', 'evaluation of baseline if that the assessment is performed prior to dosing.', 'All vital sign summaries will include the patients in the Double-blind Safety Population', 'who have at least a postbaseline time point (for criteria based on postbaseline', 'assessments) and with both a baseline and at least 1 postbaseline time point (for criteria', 'evaluating changes from baseline).', 'Clinically notable vital signs will be identified based on the criteria defined in the SAP.', 'For each vital sign parameter, the number and percentage of patients with at least 1', 'notable value will be tabulated by week and overall for the Double-blind Phase.', 'All vital signs will be listed in by-patient listings, including visit and collection date/time,', 'and will be sorted by patient identifier and date/time of assessment.', 'Electrocardiogram results include an overall interpretation of \"normal, \\'abnormal but not', \"clinically significant,' or 'abnormal and clinically significant. These results will be\", 'tabulated at each time point.', 'Electrocardiogram results will be listed for each visit, including visit, whether ECG was', 'performed (yes/no), explanation (if not performed), assessment date/time, study date,', 'overall interpretation, and relevant medical history number or adverse event number, if', 'deemed a clinically significant abnormality.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}